3rd edition

IDEA Summit
STRASBOURG - 2015
Innovation in Diabetes: European Action Summit

NOV. 30th & DEC. 1st

PROGRAM

www.idea-summit-diabetes.com
We are honored to welcome you to the 3rd edition of IDEA Summit. Organized by Lund University Diabetes Center, Eurasanté and NHL Cluster and supported by Novo Nordisk, AstraZeneca, Sanofi and Genfit, IDEA Summit is a unique European event entirely dedicated to collaborative research and technology transfer in the field of diabetes. The aim of this meeting is to be a platform for dialogue and strengthen the link between academia and industry. Through dialogue and discussions we want to bridge the gap in order to stimulate collaborative research for prevention, diagnosis and treatment of diabetes and its complications.

At IDEA Summit’s previous editions, it became clear that academia and industry made progress in understanding each other’s strengths and driving forces. However, there is still a great need to continue to develop new ways to stimulate interaction and more effective knowledge and resources sharing, and even go further and involve patients by creating sustainable links between academics and clinicians.

The different panels will provide a framework of wider discussions on bottlenecks that contribute to slow translation of diabetes research and on what can be done to bridge the existing gaps. Moreover, the partnering will give the opportunity to engage new collaborating opportunities and dialogues among the stakeholders in this field.

Thanks to the quality and diversity of its participants, IDEA Summit looks certain to generate this year again: strategic partnership opportunities and concrete take-home messages for further consideration.

We wish you all an enjoyable event full of learning and partnerships.

IDEA Summit 2015 organizers team
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide.

GENFIT’s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel.

Elafibranor is GENFIT’s lead pipeline product for the treatment of NASH, a major recognized unmet medical need.

OUR MISSION: THERAPEUTIC AND DIAGNOSTIC INNOVATION

IDEA Summit 2015 received the support of a prestigious Steering Committee, whose role is to:

• help the organizers identify optimal strategies for the implementation of IDEA Summit
• be the ambassadors of the event
• steer the content of the conference program
• help identify high-level speakers

ABOUT THE ORGANIZERS

LUND UNIVERSITY DIABETES CENTER
LUDC is a consortium of research groups at Lund University headed by Pr Leif GROOP dedicated to unraveling the pathogenesis and treatment of diabetes mellitus.

EURASANTÉ
Eurasante is the economic development agency focusing on biotech, nutrition and healthcare activities in Northern France. It assists French and foreign companies interested in developing their activities or setting-up a business in Northern France. Eurasante provides many services such as aid in accessing public subsidies, support in real-estate research, assistance with administrative formalities, human resources services, market and regulatory expertise. It also promotes the Eurasante Bio-business Park, which already hosts 7 hospitals, 4 universities, 7 specialized schools and more than 150 companies. It benefits from an exceptional location in the heart of Europe (near Paris, London, Brussels...).

NUTRITION HEALTH LONGEVITY CLUSTER
NHL Cluster is a dynamic network focusing on today’s main health issues, at the crossroads of Nutrition, Biotechnology, and Health. Its mission is to federate and support players in the Food and Health sectors in designing, developing, and financing the products and processes of the future. In the Health sector, NHL focuses on developing preventive, diagnostic, and therapeutic solutions applicable to cardiovascular and metabolic conditions, neurodegenerative diseases and Inflammatory Bowel Diseases (IBD). Its projects in the Food sector aim at protecting health and well-being through a safe, healthy, and sustainable diet.
IDEA SUMMIT 2015

AGENDA

DAY 1 • MONDAY, NOVEMBER 30TH

CONFERENCES • SCHUMANN ROOM - 1ST FLOOR

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Pre-competitive consortia &amp; bilateral collaborations: are these classic models enough to speed up innovation?</td>
</tr>
<tr>
<td>10:30 am</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>10:30 am</td>
<td>How to bridge the gap between research and clinic: an overview of national initiatives</td>
</tr>
<tr>
<td>11:00 am</td>
<td>LUNCH</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Patient empowering: how can they get more involved in future treatment solutions and funding diabetes research?</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Patient empowering: how can they get more involved in future treatment solutions and funding diabetes research?</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>LUNCH</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>CeeD Workshop: Beta cells and type 1 diabetes treatment: from the bench to the bed side</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Most successful/innovative SMEs in 2014/2015 in diabetes: find out their success story and financing map</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>LUNCH</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>CLOSING REMARKS</td>
</tr>
</tbody>
</table>

DAY 2 • TUESDAY, DECEMBER 1ST

PARTNERING EXHIBITION HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am</td>
<td>REGISTRATION AND EXHIBITION OPENING/ WELCOME COFFEE</td>
</tr>
<tr>
<td>9:00 am</td>
<td>ONE-TO-ONE MEETINGS</td>
</tr>
<tr>
<td>10:30 am</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>10:30 am</td>
<td>ONE-TO-ONE MEETINGS</td>
</tr>
<tr>
<td>10:45 am</td>
<td>LUNCH</td>
</tr>
<tr>
<td>10:45 am</td>
<td>ONE-TO-ONE MEETINGS</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>LUNCH</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>ONE-TO-ONE MEETINGS</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Presenting technologies Cardio metabolic diseases</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>ONE-TO-ONE MEETINGS</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Presenting technologies Medical Devices &amp; Imaging</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>ONE-TO-ONE MEETINGS</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Networking Evening - BioPARTY</td>
</tr>
</tbody>
</table>

For more information and to contact us visit http://www.novonordisk.com/rnd/partnering.html

Novo Nordisk is a world leader in diabetes care and has a leading position within haemostasis management and growth hormone therapy. We have refined our protein competencies since 1923, and have developed world class expertise in driving proteins from molecule to market.

We continuously look for new partnerships.

- **DIABETES & OBESITY**
  Novel proteins or peptides affecting any aspect of diabetes or obesity; Novel treatments for diabetes complications and T1D.

- **HAEMOPHILIA**
  Novel non-replacement therapies that improve haemostasis.

- **TECHNOLOGY**
  Technologies for expressing, modifying or producing proteins and peptides; Formulation and drug delivery technologies for proteins and peptides.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 190 countries. For more information, visit novonordisk.com.
Pre-competitive consortia & bilateral collaborations: are these classic models enough to speed up innovation?

This session will discuss:
- Whether pre-competitive consortia & bilateral collaborations are complimentary; How does one lead to the other?
- What are the pros & cons, the outputs of each model?
- Are these 2 models enough for translating research faster or are alternative models needed in order to speed up innovation?

How to bridge the gap between research and clinic: an overview of national initiatives

This session will focus on:
- An overview of different models at national levels fostering collaborative research and supporting/financing concrete outputs
- How to get the healthcare systems more involved in diabetes research
- How to initiate & support national initiatives in order to foster academia-industry collaborations between countries

MODERATOR:
ANNE-DOMINIQUE LAJOIX, PROFFESSOR, UNIVERSITY OF MONTPELLIER

« Pharmaceutical innovation is slowing down since the early of 2000s, to such an extent that new R&D models must be invented. Early collaborations between academic and industrial partners, as well as partnership between biotech and pharmaceutical companies, could be part of these new models. In this session, we will discuss the pertinence of pre-competitive consortia and bilateral collaborations to improve innovation. At what stage collaborations should be engaged? Join us to discuss these new innovation paradigms. »

ANNE-DOMINIQUE LAJOIX

MODERATOR:
STEFANIE POSSEKEL, DIRECTOR TECHNOLOGY MANAGEMENT, ASCENION

« In this session we will learn about exciting models of national support that help to channel novel approaches to fight diabetes through development and to the patients. Our speakers will present the situation in Sweden, France, Israel and Singapore and will show you how they work on a good alignment of all stakeholders involved in the framework of their respective healthcare systems. »

STEFANIE POSSEKEL
Patient empowering: how can they get more involved in future treatment solutions and funding diabetes research?

This session will tackle:
- How can patient groups become stronger and more involved in diabetes research?
- How to raise more awareness among diabetes type II patients? (how to organize, what could they do?)
- What roles do patient groups play today and what could their role be tomorrow?

Soffia Gudbjörnsdóttir, Director, Swedish National Diabetes Register

Magda Gunn, Scientific Project Manager, IMI - Innovative Medicines Initiative

Snorre Rubin, Patient Advocate, Type 1 Diabetes Netvaerk

Hermann von Lilienfeld, Vice-President of the Board, German Diabetes Association

“Patient empowerment starts with involving people in decisions about their treatment and should go much further than that. In this discussion, we’ll explore the potential for people with diabetes to collaborate in transforming the way diabetes is researched, managed and understood.”

Melissa Holloway, Chief Advisor, Input Patient Advocacy

Beta cells and type 1 diabetes treatment: from the bench to the bed side

The Islets of Langerhans are commonly referred to as "islets". Islets actually are clusters of cells. Within each islet there are several types of cells, which work together to regulate blood sugar. One cell type is the beta cell. Beta cells sense sugar in the blood and release the necessary amount of insulin to maintain normal blood sugar levels. The loss of these cells means the body can no longer produce insulin, the hormone required to convert food into energy for the body's cells.

Therefore, the insulin-producing islet cells cease to function in persons with diabetes. The aim of this workshop is to bring together the complementary expertise present in Strasbourg on the theme of islets starting with the differentiation, then the functionality and ending with its use in cell therapy.

Chairman:
Dr Gerard Gradwohl, Research Team Leader, IGBMC, Strasbourg
- Role of transcription factors in pancreatic beta cell development and function

Dr Romeo Ricci, Research Team Leader, IGBMC, Strasbourg
- Lysosomal degradation of insulin in the beta cell: a new paradigm in diabetes treatment

Dr Elisa Maillard-Pedracini, R&D Manager, CeeD, Strasbourg
- Beta cell replacement: a strategy to cure type 1 diabetic patient
Most successful/innovative SMEs in 2014/2015 in diabetes: find out their success story and financing map

This session will discuss:
- How to go from idea to form a company
- What were the hurdles to overcome, what can be improved for the future?
- The financing map of the company
- Important deals/alliances with academia & big players

"Developing a new therapy is exceptionally difficult. The biotech entrepreneur must find great science, recruit phenomenal researchers and executives, raise funds from investors, and develop the other resources necessary to succeed. Four of the world’s most innovative diabetes companies will share their stories, and engage in a candid dialogue about the challenges they faced throughout their respective journeys."

MIKE MORADI
Strasbourg, an attractive, innovation-led eurometropolis

The heartbeat of the Rhine basin and Alsace, Strasbourg occupies a strategic position between France, Germany and Switzerland, in the centre of Europe. The city’s growth dynamic is driven by an innovative economy, a world-class university which works closely with industry, and a comprehensive real estate offering.

Strasbourg is located in the centre of the world famous biovalley (in the 3-border region shared between France, Germany and Switzerland), which is host to some 40% of the worldwide leaders in the pharmaceutical industry. Pharmaceutics is of prime importance to Alsace as it involves some 300 companies with just under 25,000 employees, making the region the 2nd largest healthcare campus in France, just after the Greater Paris region.

Strasbourg, a lifestyle shared with the world

Strasbourg’s long tradition of hospitality makes it the ideal host for people and languages from all over the world. The city is actively committed to helping its foreign visitors feel as comfortable as possible.

Some 4 million people visit Strasbourg every year, including 2 million at Christmas. There’s a surprise every minute in the streets of Christmas – entertainment, friendship, music and laughter.

Strasbourg has all the assets to take on an innovative and responsible economic development dynamic resolutely turned towards Europe. In a context marked by major economic changes, our city may well assert itself as the “European laboratory” where the future is built.

PARTNERING DURING BIOFIT

As an IDEA SUMMIT participant, get access to BioFIT business convention on December 1st & 2nd

BioFIT is where collaborative research & tech transfer alliances get started. Featuring partneringONE system, the business convention enables you to meet up to 30 companies over 2 days, an opportunity to boost up licensing deals and perform strategic partnerships!

How to use partneringONE?

1. Check your schedule at the partnering terminals
2. Print out your schedule
3. Meet with key opinion leaders in Life Sciences

Powered by partneringONE®

About the participants

10% Investors, Professional services and Consulting
35% Technology Transfer professionals, IP and Licensing / Research institutes / Academia
35% Biotech, R&D services companies
20% Pharma, Medtech, IVD companies

Not yet active on partneringONE?

It is still time to book your meetings with BioFIT participants:

3M PURIFICATION, AALBORG UNIVERSITY HOSPITAL, ABSISKEY, ADX NEUROSCIENCES, AMGEN, ANRT, ASCENION, ASTRAZENECA, ATLANTIC BONE SCREEN, BAYER HEALTHCARE, BIO-Bмерж, BIO-RAD ABD SEROTEC, BOEHRINGER INGELHEIM, BRAIN & SPINE INSTITUTE (ICM), BREV IDEAS, BRIGHTLANDS CHEMELOT CAMPUS, CATALENT, CEA LIFE SCIENCES DIVISION, CEA SAICLAY – SITECOS, COVANCE, DEBIOPHARM INTERNATIONAL, DIAGNOSTIC SYSTEMS SOLUTIONS, DIAMOND BIOFUND, ELI LILLY, GALAPAGOS NV, GSK - GLAXOSMITHKLINE, SERVER, IOGB TTO S.R.O, JANSSEN R&D, JOHNSON & JOHNSON INNOVATION, KAUNAS UNIVERSITY OF TECHNOLOGY, LONZA, LUDI – LUND UNIVERSITY DIABETES CENTRE, MAX PLANCK INSTITUTE – CBS, MEDICAL UNIVERSITY OF GRAZ, MENARINI NOVARTIS PHARMA AG, NOVO NORDISK, PFEIZER, PHARMUIDE NV, PROVAX – UNIVERSITY OF GENT, RADEOUD UNIVERSITY MEDICAL CENTER, ROCHE, SANOFI, STALLERGENES, TEVA PHARMACEUTICAL INDUSTRIES, UCB BIOPHARMA SRL, UNIVERSITE DE STRASBOURG, UNIVERSITY OF ANTWERP, UNIVERSITY OF OXFORD, UNIVERSITY OF VIENNA, VETERINARY RESEARCH INSTITUTE, ZPROCHEM, ZEUZES, and so many others...
Hosted by

Organized by

S P O N S O R S

AstraZeneca

novo nordisk®

SANOFI

GENFIT

TOWARDS BETTER MEDICINE

S U P P O R T E R S  A N D  A C A D E M I C  P A R T N E R S

Egid

CEED

DZD

WORLD OBESITY

I N S T I T U T I O N A L  P A R T N E R S

Région Alsace

Strasbourg.eu

Université de Strasbourg

Nord Alsace

Hauts de France

EURASANTE / NHL CLUSTER
Margaux SATOLA
IDEA Summit Project Manager
msatola@eurasante.com
+33 (0)3 59 39 01 82

LUND UNIVERSITY
DIABETES CENTER (LUDC)
Thomas GUNNARSSON
LUND University & SWElife – the National Innovation Programme for Life Science, Project Manager
thomas.gunnarsson@med.lu.se
+46 40 39 11 84

© Graphisme : Laurence Laborie
Printed on recycled paper